SCOTUS rules unanimously in favor of Sanofi and Regeneron in PCSK9 patent spat with Amgen

Zachary Brennan

Senior Editor

In a closely fought patent battle between PCSK9 rivals Amgen and Sanofi/Regeneron, the Supreme Court ruled unanimously on Thursday that Amgen cannot monopolize the market for any and every antibody that binds to areas of the sweet spot of PCSK9.

The win for Sanofi and Regeneron is a setback for companies like Amgen who are looking to patent broad categories of antibodies, but cannot produce each of the antibodies that might fall into such a category.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

SCOTUS rules unanimously in favor of Sanofi and Regeneron in PCSK9 patent spat with Amgen

Zachary Brennan

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

The next generation of AI biotechs is here. Can they deliver on the hype?

Gilead leans on CymaBay liver drug, Trodelvy readouts and long-active PrEP yet to come this year

Bristol Myers outlines ‘about 12’ pipeline cuts as it executes major cutbacks

GSK accuses Pfizer and BioNTech of mRNA patent infringement

SCO­TUS rules unan­i­mous­ly in fa­vor of Sanofi and Re­gen­eron in PC­SK9 patent spat with Am­gen

Zachary Brennan

Senior Editor

Unlock this article instantly by becoming a free subscriber.

more like this

Up­dat­ed: FDA ap­proves Pfiz­er’s he­mo­phil­ia B gene ther­a­py, with $3.5M price tag

UCB makes ma­jor man­age­ment changes; Bris­tol My­ers’ ADC part­ner tops list of new CEOs

The next gen­er­a­tion of AI biotechs is here. Can they de­liv­er on the hype?

Gilead leans on CymaBay liv­er drug, Trodelvy read­outs and long-ac­tive PrEP yet to come this year

Bris­tol My­ers out­lines ‘about 12’ pipeline cuts as it ex­e­cutes ma­jor cut­backs

GSK ac­cus­es Pfiz­er and BioN­Tech of mR­NA patent in­fringe­ment

SCOTUS rules unanimously in favor of Sanofi and Regeneron in PCSK9 patent spat with Amgen

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

The next generation of AI biotechs is here. Can they deliver on the hype?

Gilead leans on CymaBay liver drug, Trodelvy readouts and long-active PrEP yet to come this year

Bristol Myers outlines ‘about 12’ pipeline cuts as it executes major cutbacks

GSK accuses Pfizer and BioNTech of mRNA patent infringement